YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
Pfizer PFE announced that the FDA has approved its marketed drug, Tukysa (tucatinib), in combination with Roche's RHHBY Herceptin (trastuzumab) and Perjeta (pertuzumab) for the maintenance treatment of adult patients with unresectable loca…
Company Logo Forecasts by application, technology and care setting show where hospital and outpatient lab spending is shifting, with strategies from 64 players including Roche, Abbott and Siemens Healthineers. Dublin, Oct. 08, 2026 (GLOBE…
Company Logo Five-year forecasts by application, technology, product and setting, from clinical labs to point of care, as syndromic multiplex panels reshape molecular diagnostics after the pandemic. Dublin, Oct. 08, 2026 (GLOBE NEWSWIRE) -…
Roche Holding has delivered a strong multi year share price run, and with the stock last closing at CHF 360.00 the live question is whether that price still lines up with what its earnings support. Recent product milestones and licensing d…
LVMH, Hermès, and Kering shares have fallen sharply, but slowing sales growth could keep pressure on the luxury sector. Continue Reading
A Dutch court rules in favor of Halozyme Therapeutics, barring Merck from selling subcutaneous Keytruda in eight European markets. Continue Reading
Investors looking for stocks in the Large Cap Pharmaceuticals sector might want to consider either Bayer Aktiengesellschaft (BAYRY) or Roche Holding AG (RHHBY). But which of these two companies is the best option for those looking for unde…
Company Logo 281-Page Report Tracks Post-Pandemic Research Growth Across Pharma, Research and Industry/Cosmetic Users as 3D Assays, Automation and Immuno-oncology Reshape Drug Discovery Dublin, Oct. 07, 2026 (GLOBE NEWSWIRE) -- "Cell-Based…
Roche Diagnostics has provided two molecular testing instruments to Institut National de Santé Publique (INSP) to support Ebola testing capacity in the DRC. Roche will preconfigure the instruments and train local laboratory technicians bef…
In September 2026, Chugai Pharmaceutical reported that Roche will discontinue development of the anti-latent myostatin antibody emugrobart for obesity and return all rights, after interim Phase II data suggested clinically meaningful weigh…
The SERD market is expected to grow significantly due to factors like improved diagnosis, treatment advancements, demographics, increased awareness, and supportive regulations in the 7MM. Additionally, the recent approvals of SERD drugs su…
Investing.com -- Goldman Sachs initiated coverage of 10 European luxury stocks, assigning Buy ratings to just four, as it argued that muted sector growth will not last and that 2027 will mark a turning point after three years of post-COVID…
Bond markets are throwing out fresh stress signals, with investors racing toward German Bunds and dumping riskier debt across Europe. That kind of flight to safety can punish cyclical stocks and fragile balance sheets, yet it can also shin…
Company Logo The global biomarkers market is projected to grow from USD 67.95 billion in 2026 to USD 112.10 billion by 2031, registering a 10.5% CAGR. Growth is driven by precision medicine, companion diagnostics, AI, bioinformatics, digit…
Company Logo The global disposable medical device sensors market is projected to grow from USD 11.86 billion in 2026 to USD 16.13 billion by 2031, registering a 6.4% CAGR. Growth is driven by chronic and infectious diseases, remote patient…
F. Hoffmann-La Roche Ltd New real-world results for Vabysmo in nAMD, DME and RVO reinforce robust effectiveness and durability across previously untreated and treated eyes, with no new safety signals1-3 Advanced AI-enabled analysis of imag…
New real-world results for Vabysmo in wet AMD, DME and RVO reinforce robust effectiveness and durability across previously untreated and treated eyes, with no new safety signals Advanced AI-enabled analysis of imaging confirms rapid and me…
F. Hoffmann-La Roche Ltd Giredestrant plus everolimus reduced the risk of disease progression or death by 44% and 62% in ITT and ESR1-mutated populations, respectively, versus standard endocrine therapy plus everolimus1 By targeting resist…
Giredestrant plus everolimus reduced the risk of disease progression or death by 44% and 62% in ITT and ESR1-mutated populations, respectively, versus standard endocrine therapy plus everolimus By targeting resistance to endocrine treatmen…
Investors looking for stocks in the Retail - Jewelry sector might want to consider either Signet (SIG) or Compagnie Financiere Richemont AG (CFRUY). But which of these two stocks is more attractive to value investors? We'll need to take a…
[A laboratory technician in a fertility clinic carefully fertilizes an egg under controlled conditions.] Tempura/E+ via Getty Images * Roche (RHHBY [https://seekingalpha.com/symbol/RHHBY]) on Wednesday said that TIB MOLBIOL, a subsidiary o…
F. Hoffmann-La Roche Ltd Fenebrutinib cut relapses by 51% and 58% vs teriflunomide in Phase III RMS trials (FENhance 1 & 2) while showing a consistent, positive trend in delaying disability1 Fenebrutinib became the first investigational me…
This test expands Roche's early diagnostics portfolio by screening for Spinal Muscular Atrophy (SMA), Severe Combined Immunodeficiency Disease (SCID), and Sickle Cell Disease (SCD) simultaneously. Catching these conditions shortly after bi…
Fenebrutinib cut relapses by 51% and 58% vs teriflunomide in Phase III RMS trials (FENhance 1 & 2) while showing a consistent, positive trend in delaying disability Fenebrutinib became the first investigational medicine in more than a deca…
Led by newly appointed CEO Dr. Prasun Mishra (ex-Genentech, Roche, NIH), Longevica leverages data from 16,000+ test subjects and 1,033 compounds to power AI discovery, drug repurposing, pet therapies, and novel therapeutic development to e…
BCC Research LLC "BCC Research examines how AI is improving biomarker detection, ctDNA analysis, early cancer diagnosis and disease monitoring while advancing precision oncology and clinical decision-making." Boston, Sept. 29, 2026 (GLOBE…
New Graphwise Platform capabilities to be showcased live at the Graphwise AI Summit 2026 NEW YORK, Sept. 29, 2026 /PRNewswire/ -- Graphwise, a leading provider of AI context platforms, today announced major updates to its AI Context Platfo…
Expansion adds 211,000 square feet to the site, supported by approximately 200 construction jobs Investment creates approximately 250 high-wage jobs pairing manufacturing expertise with digital skills in AI, automation and robotics New fac…
Roche's push into the obesity market has received another boost after its experimental drug, enicepatide, helped overweight or obese patients with type 2 diabetes improve blood sugar control while losing an average of 15.5% of their body w…
Merck MRK and partner Daiichi Sankyo announced that they have voluntarily withdrawn a regulatory filing with the FDA seeking accelerated approval for an investigational antibody-drug conjugate (ADC) called ifinatamab deruxtecan in lung can…
Roche Holding (SWX:ROP) announced new R&D alliances focused on AI-powered therapeutics and metabolic disease programs in late September 2026. The group signed a research partnership with Earendil Labs to apply AI to bispecific antibody can…
Exelixis EXEL recently suffered a setback in its efforts to get investigational candidate zanzalintinib approved. On Sept. 10, 2026, Exelixis announced that the FDA had extended the review period for its new drug application (NDA) for zanz…
Recursion Pharmaceuticals RXRX continues to leverage its AI-native drug discovery platform through a broad portfolio of pharma, technology and data partnerships. These collaborations are expanding its pipeline while generating non-dilutive…
Company Logo Opportunities center on automated, standardized TDM kits integrated with AI dosing tools for antimicrobial stewardship, transplant care and precision medicine, especially in Asia-Pacific. Dublin, Sept. 24, 2026 (GLOBE NEWSWIRE…
Atavistik Bio, Inc. Collaboration leverages Atavistik Bio's proprietary AMPSTM platform to identify and advance novel allosteric small molecules against multiple targets for cardiometabolic diseases Atavistik Bio to receive $70 million upf…
Company Logo The global pharmaceutical drug delivery market is projected to grow from USD 2.15 trillion in 2026 to USD 2.92 trillion by 2031, registering a 6.3% CAGR. Growth is driven by rising chronic disease prevalence, biologics, biosim…